PROF
Profound Medical Corp.
NASDAQ · Healthcare · Medical - Devices · CA
$6.89
+1.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 19.0M | 16.4M | 10.2M | 7.2M | 6.7M |
| Cost of Revenue | 5.4M | 4.8M | 3.5M | 2.8M | 3.7M |
| Gross Profit | 13.6M | 11.6M | 6.7M | 4.4M | 3.0M |
| Operating Expenses | |||||
| R&D Expense | 20.5M | 21.0M | 16.2M | 14.4M | 14.7M |
| SG&A Expense | 28.4M | 32.6M | 22.0M | 18.6M | 17.9M |
| General & Admin Expense | 14.8M | — | — | 9.2M | 9.5M |
| Selling & Marketing Expense | — | — | — | 9.5M | 8.5M |
| Other Expenses | — | — | — | — | 2.5M |
| Total Operating Expenses | 48.9M | 53.6M | 38.2M | 33.0M | 35.1M |
| Cost and Expenses | 54.3M | 58.4M | 41.6M | 35.8M | 38.8M |
| Operating Income (EBIT) | (35.3M) | (42.0M) | (31.5M) | (28.6M) | (32.1M) |
| Non-Operating | |||||
| Interest Income | 828.4K | 1.1M | 1.4M | 1.6M | 1.0M |
| Interest Expense | — | — | — | 770.0K | 167.1K |
| Net Interest Income | 828.4K | 1.1M | 1.4M | 872.0K | 882.6K |
| Other Non-Op Income/Expense | 2.8M | (1.1M) | 5.0M | (81.0K) | 3.7M |
| Non-Operating Income (excl Interest) | (1.6M) | — | (5.0M) | (689.0K) | (3.9M) |
| EBT (Pre-Tax Income) | (32.4M) | (43.1M) | (26.5M) | (28.7M) | (28.4M) |
| Income Tax Expense | 226.7K | 256.4K | (1.9K) | (128.0K) | 287.0K |
| Bottom Line | |||||
| Net Income | (32.6M) | (43.3M) | (26.5M) | (28.6M) | (28.7M) |
| Earnings from Cont. Ops | (32.6M) | (43.3M) | (26.5M) | (28.6M) | (28.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.6M) | (43.3M) | (26.5M) | (28.6M) | (28.7M) |
| Per Share | |||||
| Basic EPS | ($0.99) | ($1.43) | ($1.07) | ($1.35) | ($1.38) |
| Diluted EPS | ($0.99) | ($1.43) | ($1.07) | ($1.35) | ($1.38) |
| Revenue Per Share | $0.52 | $0.54 | $0.41 | $0.34 | $0.32 |
| Shares | |||||
| Basic Shares Outstanding | 36.4M | 30.2M | 24.8M | 21.2M | 20.8M |
| Diluted Shares Outstanding | 36.4M | 30.2M | 24.8M | 21.2M | 20.8M |
| Profitability Metrics | |||||
| EBITDA | (33.2M) | (41.4M) | (25.6M) | (26.8M) | (26.6M) |
| D&A | 489.6K | 569.8K | 891.1K | 1.1M | 1.6M |
| EBIT | (33.7M) | (42.0M) | (26.5M) | (27.9M) | (28.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026